{"entity":{"id":"nct07131319","kind":"trial","name":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC","aka":[],"tldr":"A phase 2/3 trial in lung cancer, run by Second Affiliated Hospital of Nanchang University, now recruiting.","summary":"SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC is a phase 2/3, interventional study registered as NCT07131319 by Second Affiliated Hospital of Nanchang University, with a registry enrolment figure of 30 participants, started 2025-04-21 and due to reach its primary completion in 2028-10-31. Interventions recorded: Spatially Fractionated Radiotherapy (SFRT); Tislelizumab, Carboplatin, Pemetrexed; Tislelizumab, paclitaxel, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: Surgical resection rate. Lung eligibility wording from the registry: \"* The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07131319","url":"https://clinicaltrials.gov/study/NCT07131319"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07131319","phase":"2/3","setting":"Spatially Fractionated Radiotherapy (SFRT) Synchronized With Tislelizumab Plus Platinum-based Dual-agent Chemotherapy for Induction Treatment of Initially Unresectable Stage III Non-small Cell Lung Cancer: A Clinical Study","sponsor":"Second Affiliated Hospital of Nanchang University","participation":[{"nct":"NCT07131319","source":"https://clinicaltrials.gov/study/NCT07131319","fetchedAt":"2026-10-07T16:55:28.490Z","studySha256":"29e0120fd85e0c46bf52f141c87fc08d2aa51972293071b3eb9a11f6fb295948","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-25","leadSponsor":"Second Affiliated Hospital of Nanchang University","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"85 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-04-21","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07131319/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}